Danaher, Recursion Pharmaceuticals, and Moderna are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks refer to publicly traded companies that are involved in the research, development, and commercialization of biotechnological products and services. These stocks are typically associated with the healthcare sector and can be affected by factors such as regulatory approvals, clinical trial results, and market demand for innovative medications and treatments. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of DHR traded up $3.07 during trading hours on Friday, hitting $206.66. The stock had a trading volume of 4,791,695 shares, compared to its average volume of 4,107,031. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40. The firm has a market cap of $149.26 billion, a P/E ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. The company’s fifty day simple moving average is $229.53 and its 200 day simple moving average is $249.51. Danaher has a 12-month low of $196.80 and a 12-month high of $281.70.
Read Our Latest Research Report on DHR
Recursion Pharmaceuticals (RXRX)
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Shares of RXRX traded up $2.03 during trading hours on Friday, hitting $10.53. The stock had a trading volume of 82,298,499 shares, compared to its average volume of 18,530,172. The company’s fifty day simple moving average is $7.27 and its 200 day simple moving average is $6.92. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. Recursion Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $15.74. The firm has a market cap of $4.11 billion, a P/E ratio of -6.88 and a beta of 0.86.
Read Our Latest Research Report on RXRX
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
NASDAQ:MRNA traded up $1.07 during mid-day trading on Friday, hitting $32.99. The company had a trading volume of 25,297,536 shares, compared to its average volume of 12,567,232. The business has a fifty day simple moving average of $39.09 and a 200-day simple moving average of $55.77. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. Moderna has a 1 year low of $29.25 and a 1 year high of $170.47. The firm has a market capitalization of $12.70 billion, a price-to-earnings ratio of -5.67 and a beta of 1.59.
Read Our Latest Research Report on MRNA
See Also
- MarketBeat’s Top Five Stocks to Own in February 2025
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
- MarketBeat Week in Review – 02/10 – 02/14
- 3 Consumer Staples ETFs for Stability in a Volatile Market
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now…
Should You Invest $1,000 in Danaher Right Now?
Before you consider Danaher, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Danaher wasn’t on the list.
While Danaher currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
